<DOC>
	<DOCNO>NCT01391637</DOCNO>
	<brief_summary>The purpose study determine long term safety preliminary effect HuCNS-SC cell transplant subject Connatal Pelizaeus-Merzbacher Disease ( PMD ) .</brief_summary>
	<brief_title>Long-Term Follow-Up Study Human Stem Cells Transplanted Subjects With Connatal Pelizaeus-Merzbacher Disease ( PMD )</brief_title>
	<detailed_description>Only subject underwent HuCNS-SC transplantation Protocol CL-N01-PMD enrol long term follow-up study . Subjects return site six month one year completion Phase I study annually total study duration four year . Phone call also make Investigator subject 's parent/legal guardian bi-annually conduct phone visit four-year duration study .</detailed_description>
	<mesh_term>Pelizaeus-Merzbacher Disease</mesh_term>
	<criteria>Subjects receive HuCNSSC cell Protocol CLN01PMD Subjects receive offprotocol immunosuppressive medication . Subjects concurrently enrol another investigational study .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Long term follow-up</keyword>
	<keyword>HuCNS-SC cell</keyword>
	<keyword>human central nervous system stem cell</keyword>
</DOC>